Bottom line
JFNCX vs VOO: the short answer
JFNCX (Janus Henderson Global Life Sciences Fund) and VOO (Vanguard 500 Index Fund) are both mutual funds.
But VOO is far broader, holding 520 positions to 108 for JFNCX, so beyond the top names it adds exposure JFNCX doesn't have.
VOO is cheaper at 0.03% vs 1.79% — a difference of $176 a year per $10,000 invested.
Updated Nov 19, 2026
JFNCX vs VOO side by side
| JFNCX | VOO | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Janus Henderson | Vanguard |
| Category | Global Stock | S&P 500 Index |
| Expense ratio | 1.79% | 0.03% |
| Annual cost per $10k | $179 | $3 |
| 10-yr cost on $10k (prospectus) | $1,897 | $39 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | 0% |
| 1-yr return | — | +17.8% |
| 5-yr return (annualized) | — | +14.4% |
| 10-yr return (annualized) | — | +14.8% |
| Best quarter | — | +20.5% |
| Worst quarter | — | −19.6% |
| Net assets (fund) | $5.8B | $1.7T |
| Number of holdings | 108 | 520 |
| Portfolio turnover | 3% | 2% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
3 of JFNCX's top 25 holdings also appear in VOO's top 25.
| Holding | JFNCX | VOO |
|---|---|---|
| Eli Lilly & Co. | 9.41% | 1.47% |
| Johnson & Johnson | 7.09% | 0.95% |
| AbbVie, Inc. | 4.67% | 0.69% |
Source: SEC Form N-PORT
JFNCX top 10
- Eli Lilly & Co. — 9.41%
- Johnson & Johnson — 7.09%
- AbbVie, Inc. — 4.67%
- UnitedHealth Group, Inc. — 4.54%
- AstraZeneca plc — 3.93%
- Revolution Medicines, Inc. — 3.02%
- Argenx SE — 2.63%
- Novartis AG — 2.56%
- Thermo Fisher Scientific, Inc. — 2.33%
- Praxis Precision Medicines, Inc. — 2.19%
VOO top 10
- NVIDIA Corp — 7.51%
- Apple Inc — 6.59%
- Microsoft Corp — 4.30%
- Amazon.com Inc — 3.62%
- Alphabet Inc — 3.25%
- Broadcom Inc — 2.77%
- Alphabet Inc — 2.59%
- Micron Technology Inc — 2.02%
- Meta Platforms Inc — 1.92%
- Tesla Inc — 1.84%
FAQ
What is the difference between JFNCX and VOO?
Which is cheaper, JFNCX or VOO?
Should I own both JFNCX and VOO?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.